ReviewJournal of primary care & community health
Treatment Approach of Refractory
Review in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens forBMJ open gastroenterology · 2026Pooled it
- Real-world evidence of a novel tetravalent immunoglobulin Y effectiveness and safety in patients with the refractory Helicobacter pylori infection.BMC infectious diseases · 2024Trial
- Safety and effectiveness of vonoprazan-based rescue therapy forWorld journal of gastroenterology · 2023Trial
- Association of Resistance-AssociatedAntibiotics (Basel, Switzerland) · 2026Article
- Candida serves as a reservoir associating with facilitating the survival and pathogenesis ofFrontiers in microbiology · 2026Article
- Novel non-antibiotic triple therapy forFrontiers in medicine · 2026Article
- Probiotics as Adjuvants to StandardMicroorganisms · 2025Review
- Multidisciplinary Approach Improves Eradication Rate and Safety in Refractory Helicobacter pylori Infection.Clinical and translational gastroenterology · 2025Article
- Article
- Newer Therapies for RefractoryAntibiotics (Basel, Switzerland) · 2024Review
- Article
- Current paradigms in the management of refractory Helicobacter pylori infection.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Review
- Treatment ofHeliyon · 2023Review
- Drug-ResistantDiagnostics (Basel, Switzerland) · 2023Review
- Unpacking the Racial Gap: Helicobacter pylori Infection Clearance Among Different Racial Groups.Cureus · 2023Article
- Editorial:Frontiers in cellular and infection microbiology · 2023Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.